|Bid||179.50 x N/A|
|Ask||181.04 x N/A|
|Day's Range||174.78 - 179.34|
|52 Week Range||113.36 - 230.45|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 26, 2023 - May 01, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for DUL.BE
When Greenstreet joined the drugmaker as chief operating officer in 2016, it had yet to turn its RNA-silencing technology into commercial drugs. Now, it's a nine-figure company.
Halozyme Therapeutics (HALO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Healthcare growth stocks are often sought out by investors looking for market disruptors. That’s because these stocks can potentially deliver high revenue growth, earnings, and stock price. As an evolving sector, the healthcare industry is seeing high demand for innovative solutions to high patient costs and technology-driven efficiency. Examples of healthcare growth stocks include pharmaceutical companies developing new drugs, medical device manufacturers creating innovative devices, and health